NGL FINECHEM Financial Statement Analysis
|
||
|
The Revenues of NGL FINECHEM have increased by 23.08% YoY .
The Earnings Per Share (EPS) of NGL FINECHEM has decreased by -59.05 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NGL FINECHEM Last 5 Annual Financial Results
[BOM: 524774|NSE : NGLFINE]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹318 Cr | ₹258 Cr | ₹15,168,639 Cr | ₹153 Cr | ₹153 Cr |
| Expenses | ₹249 Cr | ₹178 Cr | ₹13,192,719 Cr | ₹121 Cr | ₹121 Cr |
| Operating Profit (Excl OI) | ₹68 Cr | ₹80 Cr | ₹1,975,921 Cr | ₹32 Cr | ₹32 Cr |
| Other Income | ₹11 Cr | ₹8.02 Cr | ₹305,079 Cr | ₹4.12 Cr | ₹4.12 Cr |
| Interest | ₹1.91 Cr | ₹2.20 Cr | ₹262,571 Cr | ₹2.55 Cr | ₹2.55 Cr |
| Depreciation | ₹10 Cr | ₹8.33 Cr | ₹811,201 Cr | ₹6.30 Cr | ₹6.30 Cr |
| Profit Before Tax | ₹67 Cr | ₹78 Cr | ₹1,207,228 Cr | ₹28 Cr | ₹28 Cr |
| Profit After Tax | ₹50 Cr | ₹57 Cr | ₹833,528 Cr | ₹20 Cr | ₹20 Cr |
| Consolidated Net Profit | ₹50 Cr | ₹57 Cr | ₹811,693 Cr | ₹20 Cr | ₹20 Cr |
| Earnings Per Share (Rs) | ₹33.04 | ₹80.68 | ₹91.58 | ₹13.14 | ₹32.58 |
| PAT Margin (%) | 7.37 | 15.72 | 21.99 | 5.50 | 13.14 |
| ROE(%) | 9.63 | 27.90 | 44.76 | 8.72 | 21.85 |
| ROCE(%) | 11.96 | 33.91 | 53.53 | 11.93 | 25.25 |
| Total Debt/Equity(x) | 0.15 | 0.15 | 0.11 | 0.29 | 0.29 |
Key Financials |
||
| Market Cap | : | ₹ 1,403.9 Cr |
| Revenue (TTM) | : | ₹ 313.1 Cr |
| Net Profit(TTM) | : | ₹ 38.3 Cr |
| EPS (TTM) | : | ₹ 61.8 |
| P/E (TTM) | : | 36.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NGL FINECHEM | 4.4% | -1.1% | 73.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
NGL FINECHEM Revenues
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 23.08 % |
| 5 Yr CAGR | 19.99 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹318 Cr | 23.08 | |
| Mar2022 | ₹258 Cr | -100.00 | |
| Mar2021 | ₹15,168,639 Cr | 9,902,781.29 | |
| Mar2020 | ₹153 Cr | 0.00 | |
| Mar2019 | ₹153 Cr | - | |
NGL FINECHEM Operating Profit
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | -14.87 % |
| 5 Yr CAGR | 20.55 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹68 Cr | -14.87 | |
| Mar2022 | ₹80 Cr | -100.00 | |
| Mar2021 | ₹1,975,921 Cr | 6,118,248.35 | |
| Mar2020 | ₹32 Cr | 0.00 | |
| Mar2019 | ₹32 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -30.82 % |
| 5 Yr CAGR | 0.47 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 21.48% | -30.82 | |
| Mar2022 | 31.05% | 138.30 | |
| Mar2021 | 13.03% | -38.19 | |
| Mar2020 | 21.08% | 0.00 | |
| Mar2019 | 21.08% | - | |
NGL FINECHEM Profit After Tax
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | -11.91 % |
| 5 Yr CAGR | 25.44 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹50 Cr | -11.91 | |
| Mar2022 | ₹57 Cr | -99.99 | |
| Mar2021 | ₹811,693 Cr | 4,032,756.16 | |
| Mar2020 | ₹20 Cr | 0.00 | |
| Mar2019 | ₹20 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -53.12 % |
| 5 Yr CAGR | -13.46 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 7.37 % | -53.12 | |
| Mar2022 | 15.72 % | -28.51 | |
| Mar2021 | 21.99 % | 299.82 | |
| Mar2020 | 5.5 % | -58.14 | |
| Mar2019 | 13.14 % | - | |
NGL FINECHEM Earnings Per Share (EPS)
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | -59.05 % |
| 5 Yr CAGR | 0.35 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹33 | -59.05 | |
| Mar2022 | ₹81 | -11.90 | |
| Mar2021 | ₹92 | 596.96 | |
| Mar2020 | ₹13 | -59.67 | |
| Mar2019 | ₹33 | - | |
NGL FINECHEM Return on Capital Employed (ROCE)
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | -64.73 % |
| 5 Yr CAGR | -17.04 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 11.96% | -64.73 | |
| Mar2022 | 33.91% | -36.65 | |
| Mar2021 | 53.53% | 348.70 | |
| Mar2020 | 11.93% | -52.75 | |
| Mar2019 | 25.25% | - | |
NGL FINECHEM Share Price vs Sensex
| Current Share Price | : | ₹2,264.4 |
| Current MarketCap | : | ₹ 1,403.9 Cr |
| Updated EOD on | : | Apr 16,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 4.4% |
-1.1% |
73.9% |
| SENSEX | -2.4% |
-1% |
21.3% |
NGL FINECHEM related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | -1.3% | 6.1% | 62.6% |
| S&P BSE MIDSMALLCAP | -1.4% | 4.4% | 63.3% |
| S&P BSE HEALTHCARE | -1.8% | 1.4% | 56.4% |
| S&P BSE ALLCAP | -1.9% | 1.5% | 38.3% |
No NSE index found
You may also like the below Video Courses
FAQ about NGL FINECHEM Financials
How the annual revenues of NGL FINECHEM have changed ?
The Revenues of NGL FINECHEM have increased by 23.08% YoY .
How the Earnings per Share (EPS) of NGL FINECHEM have changed?
The Earnings Per Share (EPS) of NGL FINECHEM has decreased by -59.05 % YoY .
Check out Intrinsic Value of Peers of NGL FINECHEM
Compare Stock Analytics of Peers of NGL FINECHEM
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
